Jolle Micallef

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5828394/joelle-micallef-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104 2,102 25 38 g-index

145 2,797 3.8 4.94 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
104	Commentary on Perry et al.: New means, new measures-without discarding all the previous ones!. <i>Addiction</i> , 2022 , 117, 205-206	4.6	O
103	Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study <i>Lancet Regional Health - Europe, The</i> , 2022 , 100393		5
102	Doctor shopping for methylphenidate as a proxy for misuse and potential abuse in the 67 million inhabitants in France. <i>Fundamental and Clinical Pharmacology</i> , 2021 , 35, 751-761	3.1	3
101	Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. <i>Clinical Pharmacology and Therapeutics</i> , 2021 ,	6.1	3
100	Warning on increased serious health complications related to non-medical use of nitrous oxide. <i>Therapie</i> , 2021 , 76, 478-479	3.8	1
99	A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Safety, 2021 , 45, 37	5.1	1
98	French Pharmacovigilance Public System and COVID-19 Pandemic. <i>Drug Safety</i> , 2021 , 44, 405-408	5.1	3
97	Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. <i>Pain</i> , 2021 , 162, 770-777	8	3
96	Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network. <i>Frontiers in Psychiatry</i> , 2021 , 12, 640120	5	2
95	French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge. <i>Therapie</i> , 2021 , 76, 297-303	3.8	9
94	Ten-year trend of opioid and nonopioid analgesic use in the French adult population. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 555-564	3.8	6
93	Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID-19 Epidemic. <i>Clinical and Translational Science</i> , 2021 , 14, 163-169	4.9	7
92	Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology. <i>Therapie</i> , 2021 , 76, 111-119	3.8	O
91	Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance. <i>Frontiers in Psychiatry</i> , 2021 , 12, 639780	5	6
90	Quels sont mdicaments psychoactifs obtenus illdalement et par quels moyens ddcquisition? 10'ans ddbservation dtravers le dispositif national OPPIDUM. <i>Therapie</i> , 2021 , 76, 169	3.8	
89	Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy. <i>Therapie</i> , 2021 , 76, 365-367	3.8	7
88	Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market Fundamental and Clinical Pharmacology, 2021 ,	3.1	2

87	Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection. <i>Therapie</i> , 2020 , 75, 3	55-362	46
86	Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic. <i>Fundamental and Clinical Pharmacology</i> , 2020 , 34, 3	389-396	9
85	Addictovigilance contribution during COVID-19 epidemic and lockdown in France. <i>Therapie</i> , 2020 , 75, 343-354	3.8	25
84	Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseases. <i>Therapie</i> , 2020 , 75, 133-139	3.8	5
83	Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review. <i>BJGP Open</i> , 2020 , 4,	3.1	1
82	Orphan drug clinical development. <i>Therapie</i> , 2020 , 75, 141-147	3.8	8
81	Patients' organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia. <i>Therapie</i> , 2020 , 75, 221-224	3.8	2
80	COVID-19´and NSAIDs: Primum non nocere. <i>Therapie</i> , 2020 , 75, 514-515	3.8	4
79	Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 528-530	5.8	8
78	Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution. <i>Therapie</i> , 2019 , 74, 307-314	3.8	8
77	Venlafaxine Abuse in a Patient With a History of Methylphenidate Abuse: A Case Report. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 172-174	1.7	2
76	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 403-412	3.8	21
<i>75</i>	Reply to 'Overuse or underuse of methylphenidate in adults in France: commentary on Pauly et al. 2018' by Weibel et al. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 275-276	3.8	1
74	Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database. <i>Journal of the Neurological Sciences</i> , 2019 , 398, 196-201	3.2	18
73	A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers. <i>Clinical Neurophysiology</i> , 2019 , 130, 863-875	4.3	5
72	Patterns and profiles of methylphenidate use both in children and adults. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1215-1227	3.8	20
71	Effect of desipramine on patients with breathing disorders in RETT syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 118-127	5.3	14
70	Doctor shopping of opioid analgesics relative to benzodiazepines: A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. <i>Drug and Alcohol Dependence</i> , 2018 , 187, 88-94	4.9	17

69	Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France. <i>Fundamental and Clinical Pharmacology</i> , 2018 , 32, 188-197	3.1	O
68	Urinary retention associated with aripiprazole: Report of a new case and review of the literature. <i>Therapie</i> , 2018 , 73, 287-289	3.8	3
67	Proton pump inhibitors prescriptions in France: Main trends from 2006 to 2016 on French health insurance database. <i>Therapie</i> , 2018 , 73, 385-388	3.8	8
66	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 494-500	3.6	12
65	Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?. <i>Fundamental and Clinical Pharmacology</i> , 2018 , 32, 643-651	3.1	11
64	Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: A translational analysis. <i>Therapie</i> , 2018 , 73, 273-281	3.8	10
63	Brain Networks are Independently Modulated by Donepezil, Sleep, and Sleep Deprivation. <i>Brain Topography</i> , 2018 , 31, 380-391	4.3	19
62	Perampanel-associated self-harm ideation after dosage increase. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 243-244	2.8	2
61	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial. <i>Fundamental and Clinical Pharmacology</i> , 2018 , 32, 558	-370	26
60	Adaptability and reproducibility of a memory disruption rTMS protocol in the PharmaCog IMI European project. <i>Scientific Reports</i> , 2018 , 8, 9371	4.9	5
59	Investigating patient narratives posted on Internet and their informativeness level for pharmacovigilance purpose: The example of comments about statins. <i>Therapie</i> , 2017 , 72, 483-490	3.8	7
58	Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter". <i>Drug Safety</i> , 2017 , 40, 183-185	5.1	7
57	Advantages and limitations of online communities of patients for research on health products. <i>Therapie</i> , 2017 , 72, 135-143	3.8	19
56	Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 544-553	2.6	15
55	Drug-induced panic attacks: Analysis of cases registered in the French pharmacovigilance database. <i>Journal of Psychiatric Research</i> , 2017 , 90, 60-66	5.2	6
54	The drugs that mostly frequently induce acute kidney injury: a case´-´noncase study of a pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1341-1349	3.8	43
53	Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. <i>Annals of Family Medicine</i> , 2017 , 15, 355-358	2.9	34
52	Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect. <i>Aids</i> , 2017 , 31, 1775-1777	3.5	15

51	Third nerve palsy after influenza vaccination in inflammatory bowel disease (IBD). <i>Therapie</i> , 2017 , 72, 695-697	3.8	1
50	Methylphenidate: Gender trends in adult and pediatric populations over a 7year period. <i>Therapie</i> , 2017 , 72, 635-641	3.8	7
49	Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology. <i>Fundamental and Clinical Pharmacology</i> , 2017 , 31, 685-694	3.1	7
48	Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data". <i>Drug Safety</i> , 2017 , 40, 935-	936	1
47	Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database. <i>Fundamental and Clinical Pharmacology</i> , 2017 , 31, 226-236	3.1	8
46	Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey. <i>Fundamental and Clinical Pharmacology</i> , 2017 , 31, 126-131	3.1	3
45	Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor Performance status. <i>PLoS ONE</i> , 2017 , 12, e018	33736	15
44	Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence. <i>European Addiction Research</i> , 2016 , 22, 119-26	4.6	29
43	Neurobehavioral and Cognitive Changes Induced by Sleep Deprivation in Healthy Volunteers. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016 , 15, 777-801	2.6	14
42	Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016 , 19, 411-422	3.4	15
41	Misuse of Benzodiazepines in France 2016 , 1101-1111		2
40	Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people. <i>Cephalalgia</i> , 2015 , 35, 1172-80	6.1	18
39	Detection of signals of abuse and dependence applying disproportionality analysis. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 229-36	2.8	13
38	Example of an investigation of an "emergent" phenomenon in addiction vigilance: the case of methylphenidate. <i>Therapie</i> , 2015 , 70, 191-202	3.8	9
37	A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. <i>Orphanet Journal of Rare Diseases</i> , 2015 , 10, 74	4.2	10
36	Cannabis use: signal of increasing risk of serious cardiovascular disorders. <i>Journal of the American Heart Association</i> , 2014 , 3, e000638	6	145
35	French Specific Surveillance System for Drug Abuse. <i>International Journal of Mental Health</i> , 2014 , 43, 49-62	1.4	
34	An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. <i>Orphanet Journal of Rare Diseases</i> , 2014 , 9, 199	4.2	7²

33	Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. Journal of the Neurological Sciences, 2014 , 336, 155-60	3.2	16
32	OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundamental and Clinical Pharmacology, 2013 , 27, 672-82	3.1	36
31	Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. <i>European Addiction Research</i> , 2013 , 19, 235-44	4.6	18
30	Doctor shopping reveals geographical variations in opioid abuse. <i>Pain Physician</i> , 2013 , 16, 89-100	1.8	40
29	Assessment of abuse of tianeptine from a reimbursement database using 'doctor-shopping' as an indicator. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 286-94	3.1	29
28	Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 549-56	3.1	34
27	HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study. <i>PLoS ONE</i> , 2012 , 7, e41129	3.7	12
26	HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study. <i>PLoS ONE</i> , 2012 , 7, e53035	3.7	11
25	Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 184-90	2.6	17
24	Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling High Dosage Buprenorphine abuse. <i>Drug and Alcohol Dependence</i> , 2011 , 113, 29-36	4.9	20
23	Monitoring of benzodiazepine diversion using a multi-indicator approach. <i>International Clinical Psychopharmacology</i> , 2011 , 26, 268-77	2.2	21
22	Evolution of opioids reimbursement since 2004 from the National Database of the General Health Insurance System. <i>Therapie</i> , 2011 , 66, 369-72	3.8	12
21	Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 633-41	3.1	35
20	Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundamental and Clinical Pharmacology, 2011 , 25, 753-61	3.1	15
19	Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. <i>CNS Drugs</i> , 2011 , 25, 415-24	6.7	35
18	Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2010 , 5,	4.2	2
17	Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. <i>CNS Drugs</i> , 2010 , 24, 611-20	6.7	63
16	Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2009 , 8, 1103-10	24.1	103

LIST OF PUBLICATIONS

15	Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. <i>Psychopharmacology</i> , 2009 , 207, 201-12	4.7	9
14	Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 36-43	2.6	87
13	Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 333-40	3.8	50
12	Estimation of clonazepam abuse liability: a new method using a reimbursed drug database. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 318-24	2.2	22
11	Analysis of the benefits of vitamin cocktails in treating Charcot-Marie-Tooth disease type 1A. <i>Muscle and Nerve</i> , 2008 , 38, 1052-4	3.4	10
10	A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 284-9	1.7	28
9	Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 494-503	2.6	27
8	Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. <i>Pharmacoepidemiology and Drug Safety</i> , 2004 , 13, 473-81	2.6	52
7	Effects of subanesthetic doses of ketamine on sensorimotor information processing in healthy subjects. <i>Clinical Neuropharmacology</i> , 2002 , 25, 101-6	1.4	20
6	Comparison of methadone and high dosage buprenorphine users in French care centres. <i>Addiction</i> , 2001 , 96, 1433-41	4.6	48
5	Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. <i>European Addiction Research</i> , 2001 , 7, 32-6	4.6	35
4	N-methyl-D-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. <i>Neuroscience Letters</i> , 2001 , 303, 29-32	3.3	20
3	Neurobiology and clinical pharmacology of obsessive-compulsive disorder. <i>Clinical Neuropharmacology</i> , 2001 , 24, 191-207	1.4	56
2	Effects of lorazepam on emotional reactivity, performance, and vigilance in subjects with high or low anxiety. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 226-33	1.7	7
1	Abuse and misuse of second-generation antipsychotics: an analysis using VigiBase TM, the World Health Organisation pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> ,	3.8	O